Cite
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
MLA
Gigoux, Mathieu, et al. “Calreticulin Mutant Myeloproliferative Neoplasms Induce MHC-I Skewing, Which Can Be Overcome by an Optimized Peptide Cancer Vaccine.” Science Translational Medicine, vol. 14, no. 649, June 2022, p. eaba4380. EBSCOhost, https://doi.org/10.1126/scitranslmed.aba4380.
APA
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., … Merghoub, T. (2022). Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 14(649), eaba4380. https://doi.org/10.1126/scitranslmed.aba4380
Chicago
Gigoux, Mathieu, Morten O Holmström, Roberta Zappasodi, Joseph J Park, Stephane Pourpe, Cansu Cimen Bozkus, Levi M B Mangarin, et al. 2022. “Calreticulin Mutant Myeloproliferative Neoplasms Induce MHC-I Skewing, Which Can Be Overcome by an Optimized Peptide Cancer Vaccine.” Science Translational Medicine 14 (649): eaba4380. doi:10.1126/scitranslmed.aba4380.